Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:ENVB

Enveric Biosciences 5/14/2025 Earnings Report

Enveric Biosciences logo
$2.85 -0.32 (-10.09%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$2.83 -0.02 (-0.74%)
As of 05/8/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Enveric Biosciences EPS Results

Actual EPS
-$14.64
Consensus EPS
-$41.40
Beat/Miss
Beat by +$26.76
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Date
5/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enveric Biosciences' next earnings date is estimated for Tuesday, May 19, 2026, based on past reporting schedules.

Conference Call Resources

Enveric Biosciences Earnings Headlines

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260505587393/en/enveric-biosciences-highlights-positive-results-for-eb-003-in-ptsd-preclinical-model/
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-appoints-joseph-tucker-phd-to-board-of-directors-302755046.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
What's going on with Enveric Biosciences stock on Friday?
April 24, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/whats-going-on-with-enveric-biosciences-stock-on-friday/ar-AA21FhTv
7 Best Psychedelic Stocks and ETFs to Buy in 2026
April 21, 2026  |  money.usnews.comhttps://money.usnews.com/investing/articles/best-psychedelic-stocks-and-etfs-to-buy
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
April 20, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/04/51924642/enveric-biosciences-stock-soars-after-trumps-psychedelics-executive-order
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety. In parallel with pharmacology studies, the company is advancing formulation development, toxicology evaluations and analytical methods to support regulatory submissions and clinical trial readiness.

The company emphasizes a robust regulatory strategy and plans to file investigational new drug (IND) applications in the United States and Canada. Enveric collaborates with academic institutions, contract research organizations and clinical advisors to validate its drug candidates in emerging psychiatric therapy paradigms, including adjunctive use alongside psychotherapy.

Enveric Biosciences trades on the NASDAQ under the ticker ENVB, following a corporate rebranding from FSD Pharma in October 2021 to reflect its exclusive focus on psychedelic medicine. The company is pursuing strategic partnerships and geographic expansion across North America and Europe to accelerate clinical development and future commercialization of its pipeline assets.

View Enveric Biosciences Profile
Earnings Tools